ImmunityBio, Inc.IBRX

時価総額

$22.8億

PER

	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日
Revenue	0	0	0	0	0	0	1	0
Research and Development Expense	11	29	42	56	50	64	196	248
Selling, General and Administrative Expense	228	95	57	43	18	27	135	103
Impairment of intangible assets	-	-	-	-	-	-	-	1
Total operating expenses	-	125	99	98	68	92	331	352
Loss from operations	-	-124	-99	-98	-68	-92	-330	-351
Gain (Loss) on Investments	-	-	-	-	-	-	-4	-3
Interest expense (including amounts with related parties)	-	0	1	-	-	-	15	64
Loss on equity method investment	-0	-	-	-	-	-	-1	-12
Change in fair value of warrant liability	1	-	-	-	-	-	-	-13
Other Nonoperating Income (Expense)	0	0	0	0	0	-1	0	-1
Total other expense, net	-	3	2	2	2	-1	-20	-66
Loss before income taxes and noncontrolling interests	-	-121	-97	-97	-66	-92	-350	-417
Income tax (expense) benefit	-0	-1	-0	-1	-0	0	0	0
Net loss	-	-	-	-96	-66	-92	-350	-417
Net Income (Loss) Attributable to Noncontrolling Interest	-	-	-	-	-	-	-3	-1
Net loss attributable to ImmunityBio common stockholders	-237	-121	-96	-96	-66	-92	-347	-417
Earnings Per Share, Basic	-	-	-	-	-	-	-0.89	-1.04
Earnings Per Share, Diluted	-	-	-	-	-	-	-0.89	-1.04